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Abstract Polypeptides often display proline-mediated confor-
mational substates that are prone to isomer-specific recognition
and function. Both possibilities can be of biological significance.
Distinct families of peptidyl prolyl cis/trans isomerases
(PPIases) evolved proved to be highly specific for proline
moieties arranged in a special context of subsites. Structural
and chemical features of molecules specifically bound to the
active site of PPIases served to improve catalysis of prolyl
isomerization rather than ground state binding. For example,
results inferred from receptor Ser/Thr or Tyr phosphorylation in
the presence of site-directed FKBP12 mutant proteins provided
evidence for the crucial role of the enzymatic activity in down-
regulating function of FKBP12.
z 1998 Federation of European Biochemical Societies.
1. Introduction
Proteins, in having binding capacity for other molecules,
control cellular reactions di¡erently. In this way, enzyme pro-
teins have to convert biomolecules chemically whereas binding
proteins release biological e¡ects from complexes by realizing
togetherness. In both cases capacities for ligand binding are
required at a single site of the protein. Di¡erentiating between
the alternative functions is crucial in understanding cellular
e¡ects but not always an easy task for protein^ligand inter-
actions. Commonly, di⁄culties in studying reversible reactions
are encountered in cases of minor di¡erences of chemical
properties between the reactant and product state. Typically,
the assignment to a cellular function of peptidyl prolyl cis/
trans isomerases (PPIases), which catalyzes equilibration of
conformers, su¡ers from the lack of pronounced chemical
di¡erences between the interconverting molecules. Unlike oth-
er enzymes utilizing polypeptide substrates (proteases, protein
kinases, protein phosphatases) the catalytic mechanism of
PPIases promotes a permanent population of two ground
state Michaelis complexes upon joining a proline-containing
peptide chain and a PPIase. Originally discovered as helper
enzymes for accelerating restructuring of the polypeptide
backbone [1], these proteins have a proline-directed binding
capability proposed to be of exclusive biological importance
[2,3]. Moreover, catalysis of prolyl bond1 isomerization was
discussed as a side e¡ect attributable to the hydrophobic na-
ture of the substrate binding site of the PPIases.
To date, the existence of three families of PPIases has been
established represented by numerous proteins ubiquitously oc-
curring from primates to Archaea [4,5]. The families were
named cyclophilins (Cyp), FK506 binding proteins (FKBPs)
and parvulins [6]. The competitive inhibitors rapamycin,
FK506 and cyclosporin A display both tight binding to and
high speci¢city for di¡erentation of the PPIase families. How-
ever, dissecting PPIase functions in vivo will not succeed with
these inhibitors because active site competition simultaneously
a¡ects both complex formation and catalysis. Furthermore,
signi¢cance to cell signalling of enzyme activity cannot be
inferred from inhibitory e¡ects because of the additional bio-
activity associated with the PPIase-inhibitor complexes them-
selves [2].
However, there is a major di¡erence between the alternative
modes of action of PPIases that may serve to make a decision.
Evolved to perform catalysis, an enzyme promotes transition
state binding. Ground state binding to ligands has been the
driving force for a binding protein to evolve. Obviously, nat-
ural substrates are expected with most pronounced e¡ects in
di¡erentiating both situations but, when still unknown, struc-
ture-function relationships within series of peptides may serve
to approximate the cellular state. Similarly, site-directed mu-
tagenesis of PPIases may provide a valuable tool to distin-
guish between those functional alternatives thought to be dif-
ferently a¡ected in binding and catalysis of ligands by the
amino acid substitution.
2. Conformational diversity is intrinsic to prolyl bonds
The traditional electron resonance model describes most of
the biologically important properties of secondary amide and
imide peptide bonds, including hindered bond rotation, to be
involved. It confers splitting of prolyl bond rotational isomers
between two energetically preferred states, cis and trans, leav-
ing aside regions of dihedral angles g di¡erent from the values
of 0 þ 15‡ and 180 þ 15‡, respectively. Crossing of the barrier
between the conformations is rather costly in terms of energy.
Both states have to become populated in linear proline pep-
tides unless severe constraints are imposed by tertiary inter-
actions, crystal packing e¡ects and internal strain. In addition,
immediately after ribosomal synthesis trans prolyl bonds are
expected throughout. Adjacent amino acids exert local se-
quence e¡ects on the cis/trans ratio but cannot liberate more
than about 8 kJ/mol free energy di¡erences between the gene-
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1 The term prolyl isomerisation is used throughout the paper for the
cis/trans isomerisation of the peptide bond preceding proline in an
amino acid sequence. Similarly, the term prolyl bond is synonymous
with the peptide bond preceding proline.
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coded residues [7,8]. This energetic contribution does not suf-
¢ce to shift the cis/trans equilibrium completely to a certain
side.
The coexistence of the isomers remains constant in time in
the absence of energy-coupled vectorial processes involving
the conformers di¡erently, like membrane transport, bond
formation, bond cleavage and folding.
The vectorial events correlate with the re-equilibration of
isomers to occur. The equilibration rate is controlled by a
¢rst-order rate constant kobs equivalent to the sum of the
cisCtrans and transCcis isomerization rate constants as an
upper rate limit when the coupled process is of much slower
rate than cis/trans isomerization. At high velocity of the
coupled reaction two limiting rates become alternatively pos-
sible, depending on which of the isomers, the minor or the
major one, is preferentially sequestered into the coupled event.
For prolyl isomerizations half times may cover the range of
seconds to many minutes at ambient temperature.
Excluding N-terminal proline the number of cis/trans iso-
mers theoretically formed is given by 2n with n accounting for
the number of prolines within the sequence. The peptide chain
must have a sequence-derived predisposition to distribute to
all cis/trans states in aqueous solution. Conformational homo-
geneity roughly parallels increasing chain-length under native
conditions as was comprehensively indicated by the exclusive
isomeric state of most prolyl bonds, either cis or trans, in
biologically active proteins. The energy costs associated with
the preferential population of a certain isomer have to be
covered by favorable tertiary interactions.
Under denaturing conditions in the presence of high con-
centrations of urea or GdmHCl the peptide chain becomes
uniformly solvated. Three out of four prolines of RNase A
exhibit isomerization rates and cis/trans ratios typical of those
found in short oligopeptides [9].
More native conditions existed when NMR spectra revealed
the 16 possible prolyl isomers in a prolactin receptor-derived
octapeptide consisting of a four-proline array supplemented
with non-polar amino acids [10]. The dominance of local ef-
fects is still evident by having present all isomers at a fraction
s 1%. However, the ¢rst indication of the relevance of long-
range interactions comes from the enhanced cis fraction (70%)
of the Val-Pro-Gly moiety that does not ¢t by about 8kJ/mol
into the structure^cis/trans ratio relationship derived from
short oligopeptides [7,8].
Dramatic alterations in the cis/trans ratio were found for
three out of four prolyl bonds in a 25-mer oligopeptide cor-
responding to residues 81^125 of the HIV-1 p24 capsid pro-
tein [11,12]. Energetically, the Gly-Pro90-Ala segment behaves
normally in that the ratio of conformers did not re£ect any
in£uence of remote parts of the molecule. The segments His-
Pro85-Val, Ala-Pro93-Gly and Glu-Pro99-Arg, however, com-
pletely lack the conformational multiplicity expected stabilized
in the trans state throughout. Curiously enough, using di¡er-
ent structural probes evidence for the existence of any of the
common secondary structure elements was lacking for the 25-
mer. This observation raises the question of the origin of
energy stabilizing the pure conformational state of these prol-
yl bonds. The increasing frequency of reports about prolyl
isomerization in native proteins con¢rms that the coexistence
of conformationally homogeneous and heterogeneous prolyl
bonds in a single, folded peptide chain is a general phenom-
enon. [13^16].
3. The choice of the prolyl isomer for mediating bioactivity
There is no need to discuss enzymes that catalyze the inter-
conversion between biologically indistinguishable molecules.
However, cis/trans isomers do not belong to this type of com-
pound. They cannot sample the same conformational space
around proline [7,17], thus presenting a distinct topography to
interacting groups. In this way, a precondition for resulting
isomer-speci¢c reactions is the inability of macromolecules to
provide su⁄cient binding energy to preorganize ligands into
reactive conformations. Usually, proteins are not able to
adopt ligands containing wrong prolyl isomers giving rise to
isomer-speci¢c recognition. The question about which mole-
cule is biologically relevant among a diversity of prolyl iso-
mers was already answered in a few simple cases, but needs to
be addressed as a central concern in others. Regarding isomer
speci¢city we adopt the theory that either the ligand or the
acceptor protein undergoes isomerization. In the ¢rst case
analyses were easy to perform by measuring enzyme kinetics
under speci¢c conditions as was shown for proline-containing
substrates underlying proteolysis. Dependent on the proline
position relative to the scissile bond, a moderate to absolute
speci¢city in discriminating cis prolyl bonds was found for
many proteases [18]. The presence of PPIases completely abol-
ished realization of isomer speci¢city of substrate degradation
in vitro [1,5] and in vivo [19,20], provided that the proline
peptide could also be used as a substrate of the respective
PPIase.
Of the cis/trans conformers of Cyp18 substrates in solution,
the PPIase sequesters more the cis form, leading to a slightly
altered cis/trans ratio of the Michaelis complexes near unity
[21]. According to Burbaum et al. [22] this ratio may postulate
that cytoplasmic Cyp18 is likely to operate in vivo nearby the
cis/trans equilibrium rather than far away from it. Because the
latter situation is realized for nascent polypeptide chains cy-
clophilins might be targeted to other folding states of proteins.
Turning to another protein function, the intestinal H/pep-
tide symporter was shown to transport only trans prolyl di-
peptides from the uptake medium into Caco-2 cells, leaving
the fraction of the cis isomers unbound and thus outside the
cell [23]. In this case, kinetic control of uptake by isomer
speci¢city cannot be dissolved in cells enzymatically because
PPIases capable of catalyzing dipeptides have not yet been
detected. In other cases the bioactivity of peptide ligands
was identi¢ed to relate to either cis [15,24,25] or trans isomers
[26] using analogues that constrain critical peptide bonds.
What is more important, several examples show that the
function of native proteins can be separated by prolyl bond
isomerization [27^29]. For example, the Gly-Pro17 moiety has
been addressed to be the likely candidate of an ATP-depend-
ent induced-¢t movement in rabbit muscle. Indeed, Cyp18
caused a two-fold increase in rate for this domain movement
[30]. On the contrary, Cyp18 proved to be unable to catalyze
the native-state isomerization of Gly-Pro43 in calbindin D9K
[16], eventually indicating lack of productive binding by ster-
ical crowding.
4. Subsite interactions correlate with catalysis
Extended chain segments represent the neighborhood of
proline attached to the active cleft of complexes of Cyp18
with proline-rich polypeptides totalling nine amino acids in
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length [3,31]. This mode of binding is similar to that of ligand
peptides described for the Hsp70 family. These proteins are
representatives of another class of folding helper proteins, the
chaperones [32]. However, so far no evidence for a chaperone-
like activity of a prototypic PPIase was obtained. Thus,
Cyp18 failed to increase the refolding yield of carbonic anhy-
drase protein that su¡ers from aggregation-prone folding in-
termediates [33]. In addition, the prototypic PPIases exhibit
low a⁄nity for unfolded polypeptide chains, since relevant V/
[S] characteristics did not reveal substrate saturation up to the
upper WM range [34]. Thus, the Km values of multidentate
polypeptides approach those of short peptides in the millimo-
lar range. Similarly, the native state interaction of Cyp18 with
HIV-1 capsid protein was found to exhibit a relatively high
a⁄nity s 10 WM despite the use of multiple binding sites [35].
For comparison, dissociation constants have been measured
for SH3 domains which evolved to mediate proline-directed
protein^protein contacts. Octapeptides excised from SH3 do-
main ligands bind in the range of 10 WM [36] already, and
HIV-1 Nef exhibits avid binding below the WM range. System-
atic extension of peptide chain lengths led to quite di¡erent
e¡ects regarding ground state and transition state binding in
PPIases. According to the catalytic model of Cyp18 [21] the
Km values approximate ground state binding Ks by KsvKm
whereas kcat/Km represents complementarity to the transition
state. In going from a cis dipeptide to a cis tetrapeptide
ground state a⁄nity increases 70-fold [37]. However, kcat/Km
increases s 106-fold, indicating that binding energy of addi-
tional subsites is mainly used to increase kcat. Also, introduc-
tion of side chain phosphate on threonine in a -Ser-Pro-Arg-
moiety causes 1300-fold increase in kcat/Km for the PPIase
activity of the parvulin-like human Pin1 [38] indicating
marked transition state preference of phosphate group bind-
ing capability. In contrast to conventional PPIases like
FKBP12 and Cyp18, Pin1 (and the yeast analogue ESS1)
evolved to utilize binding energy of just a single polar subsite
to increase kcat enormously.
Beside the prototypic members of the PPIase families larger
proteins exist that possess a PPIase core supplemented with
domains of di¡erent functions. Only a few investigations exist
about the coexistence of the extra modules with the catalytic
core. However, it has been shown that the 48-kDa trigger
factor, which is a FKBP-like PPIase bound to the 50S subunit
of the E. coli ribosome, is constructed from a central PPIase
core £anked by two autonomous folding modules. The con-
siderable a⁄nity to unfolded polypeptide chains of the £ank-
ing modules did not serve to increase catalysis, but is solely
used for ground state binding [34]. Again, the excised catalytic
module alone lacks enhanced ground state a⁄nity. Conse-
quently, proline recognition is not involved in the chaper-
one-like a⁄nity of the £anking domains [39]. These domains
can thus enable a PPIase core to approach selectively cell sites
prone to protein unfolding. A similar function can be hy-
pothesized for FKBP52 because active site blocking does
not deplete its aggregation suppressing properties [40]. Re-
garding domain function the large bovine RanBP2 and £y
NinaA [41,42] might represent cyclophilin counterparts of
the FKBP-like trigger factor. Indeed, contingent on the pres-
ence of the £anking Ran-binding domain 4 of RanbP2, R/G
opsin binds stably to the cyclophilin-like PPIase. NinaA does
not have a Ran-binding domain 4 but a hydrophobic C-ter-
minal extension of the catalytic core which is well suited for
binding of a subset of opsins. Both stable binding to and
PPIase activity of the cyclophilin domain were necessary for
production of visual pigments in COS-1 cells [41].
5. Dissecting functions by site-directed mutagenesis
Once site-directed mutations are made to explore catalytic
functions of PPIases it is necessary to establish structural in-
tegrity, residual activity toward a broad range of substrates
and conservation of the binding function of the active site
cleft. Obviously, prerequisites have been evaluated only in
part for most mutant PPIases hitherto reported. For example,
FKBP12 dependent Ca2 channel properties of the muscle
ryanodine receptor could be restored with the apparently in-
active Phe99-Tyr FKBP12 variant, suggesting that enzyme ac-
tivity was dispensable for biological function [43]. This
FKBP12 variant maintained binding to the receptor, but in
a reduced manner. However, this FKBP12 variant was not
completely devoid of activity in other PPIase assays. Even
more, the ratio of activity of wt FKBP12 to mutant enzyme
depended on the amino acid sequence of the substrate [44,45].
Considering these results functional complementation by the
Phe99-Tyr FKBP12 variant does not yet rule out the necessity
of PPIase activity for ryanodine receptor function. Other re-
sults with mutant PPIases also need re-interpretation in the
light of activities monitored by improved PPIase assays [46].
Receptors provide exquisitely sensitive probes for evaluat-
ing the e¡ects of mutant PPIases because of signal ampli¢ca-
tion. Fortunately, it was possible to make use of the trans-
forming growth factor-L (TGFL) signal transduction to
dissect FKBP12 functions. FKBP12 inhibits TGFL type I re-
ceptor (TLR-I) signalling function by preventing TLR-II-
coupled phosphorylation of the Gly/Ser/Thr-rich motif of
TLR-I [47]. The Leu-Pro194 moiety succeeding the phospho-
rylation site in TLR-I proved to be critical to the FKBP12-
TLR-I interaction, since the Leu-Gly194 but not the Leu-
Phe194 mutation eliminates FKBP12 e¡ects. With oligopepti-
des, kinetic data demonstrated that the LeuCGly substitution
in the FKBP12 substrate exclusively deteriorates kcat/Km, leav-
ing binding avidity unaltered [48]. Similarly, wt FKBP12-
mediated decrease in TLR-1 phosphorylation could not be
mimicked by the Phe36-Tyr FKBP12 variant in cotransfected
R1B cells [47]. Remarkably, the same FKBP12 mutant protein
leads to contrasting results with the ryanodine receptor dis-
cussed above: restoration of biological activity with the rya-
nodine receptor vs. inability to replace wild-type enzyme with
the TLR probe. Such results have to be expected from the
substrate speci¢city of enzymes.
In another example, the e¡ect on signalling of the partial
disruption of the catalytic machinery of the Phe99-Tyr
FKBP12 variant became also apparent, but even in a simple
cell-free assay. The sequential signalling events induced by
binding of EGF to the EGF receptor (EGFR) include recep-
tor dimerization, stimulation of its intrinsic tyrosine kinase
activity and ¢nally autophosphorylation of de¢ned tyrosine
residues of the receptor protein. Negative regulation of auto-
phosphorylation after EGF stimulation was obtained by
externally added human recombinant FKBP12 in plasma
membrane fractions of A431 ¢broblasts [49]. At high concen-
trations of FKBP12 even the basal level of EGFR autophos-
phorylation is almost invisible. Replacement with low-activity
FKBP variants, like Phe99-Tyr FKBP12 and Asp37-Leu
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FKBP12, of wt FKBP12 can restore its inhibitory potential to
a small extent only. The remaining inhibitory potential was
thought to indicate residual PPIase activity of the mutant
enzymes as measured in the oligopeptide assay. According
to this model, ground state binding a⁄nity to oligopeptides
of the low-activity Phe99-Tyr FKBP12 variant was only
slightly reduced, ruling out binding as a source of the inhib-
itory e¡ect of wt FKBP12 on EGFR autophosphorylation
(T. Zarnt, unpublished). It is worth noting that PPIase spe-
ci¢city plays a crucial role in the inhibitory e¡ect. Despite
high enzyme activity toward standard substrates, neither
Cyp18 nor the FKBP-like catalytic domains of the E. coli
trigger factor were able to mimic the e¡ect of FKBP12.
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